Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai,

Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



1

Ref No: TPL PP 20250946 2025; 12th November 2025

To

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai: 400 001.

Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Outcome of the Board Meeting held on Wednesday 12th November 2025

Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements)

Regulation, 2015

We would like to inform you that, pursuant to Notice of Board meeting dated 5th November 2025 the Board Meeting of the Company was held today Wednesday 12th November 2025 at 3.00 p.m. at 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai: 400001, the registered office of the Company, In pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board has considered an approved the following:

- 1. The Board approved the Unaudited Standalone Financial Results of the Company for the quarter and half year ended on 30th September 2025, as reviewed by the Audit Committee along with Statement of Assets and Liabilities as at 30th September 2025 and Cash Flow Statement for the half year ended 30th September 2024, in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 2. The Board noted and took on records the Limited Review Report for the quarter and half year ended on 30th September 2025 submitted by the Statutory Auditors as placed before the Board.
- 3. The Board discussed and took note of the statement of deviation or variation in public issue, rights issue, preferential issue, etc. under Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended 30th September 2025 as amended as per Circular No. CIR/CFD/CMD1/162/2019, dated 24th December 2019, duly reviewed by the Audit Committee along and the auditor's comments, that, The statement of Category wise variation is also not applicable as there has been no offer made by way of

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai,

Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



Public Issue, Rights Issue, Preferential Issue, etc., during the Quarter ended 30th September 2025.

- 4. Take notes on the compliance for the quarter ended 30th September 2025.
- 5. Board Meeting commenced at 3.00 p.m. and concluded at 4.45 p.m.

You are requested to take note of the same.

Thanking you,
Yours faithfully,
For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA

DIRECTOR

DIN: 00312369 Place: Mumbai Encl.: as above



Kanu Doshi Associates LLP

Chartered Accountants

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To, The Board of Directors of TRIOCHEM PRODUCTS LIMITED ("The company")

- We have reviewed the accompanying statement of unaudited financial results of TRIOCHEM PRODUCTS LIMITED ("The company") for the quarter and half year ended September 30, 2025 being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time.
- This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. Our review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP

Chartered Accountants

Firm Registration No: 104746W/W100096

Kunal Vakharia

Partner

Membership No.: 148916

UDIN: 25148916BMKNTB5091

Place: Mumbai

Date: 12th November, 2025

3

Mumba

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544




TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com CIN: L24249MH1972PLC015544

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

C-	Dominulana		Ougeton Ended		(Rs in Lakh) Except EPS Half Year Ended Year Ended			
Sr.	Particulars	Quarter Ended						
No.		30-Sep-25 (Unaudited)	30-Jun-25 (Unaudited)	30-Sep-24 (Unaudited)	30-Sep-25 (Unaudited)	30-Sep-24 (Unaudited)	31-Mar-25 (Audited)	
1	Income	(Cillulation)	(022000)	(CAMPOALES)	(Canada Canada)	(0	()	
	(a) Revenue from Operations		-	-		-		
	(b) Other Income	29.52	22.10	26.69	51.62	49.66	105.01	
	Total Income From Operations	29.52	22.10	26.69	51.62	49.66	105.01	
2	Expenses							
	(a) Cost of Materials Consumed		- 1	-	-	1 8 1	5.29	
	(b) Purchase of stock in trade	•	* .		×			
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		, .	٠		•	, E	
	(d) Employees Benefit Expenses	13.76	13.52	14.71	27.28	29.86	58.88	
	(e) Finance Costs	-	-		-	-	-	
	(f) Depreciation and Amortisation Expenses	1.66	1.64	1.94	3.30	3.85	7.68	
	(g) Other Expenditure	28.71	22.18	14.93	50.89	30.46	57.78	
•	Total expenses	44.13	37.34	31.58	81.47	64.17	129.63	
							LOSSONION AS	
3	Profit before exceptional items and tax	(14.61)	(15.24)	(4.89)	(29.85)	(14.51)	(24.62	
4	Exceptional items (refer Note 4)	3 ⊭ 1	-	-	ي .	<u></u>	: *	
5	Profit/ (Loss) before tax	(14.61)	(15.24)	(4.89)	(29.85)	(14.51)	(24.62	
6	Tax Expense							
	(a) Current tax		-	<u> </u>		-	(11.86)	
	(b) Deferred tax	4.65	(12.18)	(1.23)	(7.53)	(3.01)	27.25	
	Total tax expenses	4.65	(12.18)	(1.23)	(7.53)	(3.01)	15.39	
7	Net Profit/ (Loss) for the period	(19.26)	(3.06)	(3.66)	(22.32)	(11.50)	(40.01	
0	Other Comments resive Income (Not of Taxon)							
8	Other Comprehensive Income (Net of Taxes) (A)(i). Items that will be reclassified to profit or loss							
		•	-	-	-		-	
	(ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	•	
	(B)(i). Item that will not be reclassified to profit or loss	(64.87)	114.15	39.34	49.28	143.41	(66.82	
	(ii). Income tax relating to items that will not be reclassified to	17.85	(24.88)	(17.03)	(7.03)	(28.97)	11.49	
	profit or loss		,		()	(,-)		
	Total other Comprehensive Income (net of taxes)	(47.02)	89.27	22.31	42.25	114.44	(55.33	
9	Total Comprehensive Income for the period	(66.28)	86.21	18.65	19.93	102.94	(95.34	
10	Paid-up equity share capital (Face Value of ₹ 10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50	
11	Other equity as per Balance Sheet of previous accounting year						1,342.19	
	Earnings per equity share (EPS) (of Rs. 10/- each) (not annualised)							
- 1	Basic / Diluted EPS (in Rs.)	(7.86)	(1.25)	(1.49)	(9.11)	(4.69)	(16.33)	



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544




TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com CIN: L24249MH1972PLC015544

			(Rs in Lakh)			
	ATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2025					
	Particulars	As at 30-Sep-25 (Unaudited)	As at 31-Mar-25 (Audited)			
A	ASSETS					
1	Non- Current Assets					
	(a) Property, plant and equipment	50.75	53.89			
	(b) Investment property	6.18	6.33			
	(c) Financial assets					
	(i) Non-current investments	1,121.80	1,062.60			
	(ii) Other financial assets	9.24	9.22			
	(d) Deferred tax assets (Net)	4.09	3.60			
	(e) Other non current assets	1.01	1.01			
	Sub Total - Non- Current Assets	1,193.07	1,136.65			
2	Current Assets					
	(a) Inventories	-	-			
	(b) Financial Assets					
	(i) Cash and cash equivalents	52.25	90.66			
	(ii) Other financial assets	0.28	0.52			
	(c) Other tax assets (net)	26.38	16.17			
	(d) Other current assets	139.41	145.09			
	Sub Total - Current Assets	218.32	252.44			
	TOTAL ASSETS	1,411.39	1,389.09			
	TOTAL ASSETS	1,411.39	1,303.09			
В	EQUITY AND LIABILITIES					
1	Equity					
	(a) Equity share capital	24.50	24.50			
	(b) Other equity	1,362.11	1,342.19			
	Sub Total - Shareholder's fund	1,386.61	1,366.69			
2	Liabilities					
5-0	(a) Current Liabilities					
	(a) Financial liabilities	1				
	(i) Trade payables	16.94	15.50			
	(b) Other current liabilities	0.51	0.53			
	(c) Provisions	7.33	6.37			
	Sub Total - Liabilities	24.78	22.40			
	TOTAL EQUITY AND LIABILITIES	1,411.39	1,389.09			



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com CIN: L24249MH1972PLC015544

CLOSS BY ONE ORIGINAL STATE OF THE STATE OF	DELOTIO SOUR CORRESPONDE	2025	(Rs in Lak	
CASH FLOW STATEMENT FOR THE HALF YEAR	ENDED 30TH SEPTEMBER		n 1 1	
Particulars	Particulars		r Ended	
		30-Sep-25	30-Sep-24	
CLOVE TO ONE TO ONE OTHER LIBERTS A COMMUNICATION	V. 4 ***********************************	(Unaudited)	(Unaudited)	
CASH FLOW FROM OPERATING ACTIVITIES		(20.05)	(1/5	
Net Profit before tax and Extraordinary Items		(29.85)	(14.5	
Adjustment for:		2.20	2.0	
Depreciation / Amortisation		3.30	3.8	
Interest Income		(0.34)	(2.1	
Dividend income on investment		(8.52)	(3.8	
Reclassification of remeasurement of employee	benefits	(0.15)	(0.9	
Interest Expenses		-	(=)	
Net Gain on sale of Investment		(9.76)	(10.6	
Investment Expenses		0.02	0.0	
Sundry balance Off			-	
Operating Profit before Working Capital Chang	es	(45.30)	(28.1	
Adjustments for Working Capital Changes				
Increase/Decrease in Assets		5.67	2.5	
Changes in Inventories		- 1		
Increase/Decrease Trade Receivable		-	· * 1	
Increase/Decrease in other financial and non-fir	ancial assets	0.22	59.3	
Increase/Decrease Trade payables		1.44	8.5	
Increase/Decrease in other financial and non-fir	ancial liabilities	-		
Increase/Decrease in Liabilities		(0.02)	(0.0)	
Changes in Provision		0.95	0.9	
Cash Generated from Operations		(37.04)	43.2	
Direct taxes paid / (refund)		(10.21)	(9.8	
Net Cash from Operating Activities		(47.25)	33.3	
CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of Fixed Assets including Capital Work	in Progress			
Purchase / (Sale) of Investment	in Hogicos			
Investment Expenses		(0.02)	(0.0)	
Dividend income on investment		8.52	3.8	
Interest Received		0.000.000	0.000	
	2 2011 18:	0.34	2.1	
Net Cash Used in Investing Activity		8.84	5.9	
CASH FLOW FROM FINANCING ACTIVITIES				
Net (Decrease)/ Increase in Short Term Borrow	ngs	-	-	
Interest Paid		-		
Net Cash Used in Financing Activity		-		
NET CHANGES IN CASH & CASH EQUIVALENTS	(A+B+C)	(38.41)	39.2	
OPENING BALANCE OF CASH & CASH EQUIVAL	ENTS	90.66	53.8	
CLOSING BALANCE OF CASH & CASH EQUIVAL		52.25	93.0	
The state of the s		38.41	(39.2	

(39.27) (39.27) (Mumbai) (Mumbai)

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com CIN: L24249MH1972PLC015544

Notes:

- 1) The above unaudited standalone financial results of the Company for the quarter and half year ended 30th September 2025 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 12.11.2025. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon.
- 2) The Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunser and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- 4) The Board of Directors, at its meeting held on 24th October 2025, has approved the proposal for the sale of immovable properties, plant & machinery and investment property of the Company situated in Maharashtra. The proposed sale constitutes a Material Related Party Transaction under the provisions of Section 188 of the Companies Act, 2013 and Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accordingly, the transaction shall be subject to approval of shareholders through postal ballot.

The said assets proposed to be sold have an aggregate written down value (WDV) of ₹56.92 lakhs. The fair market value of the assets, as determined and certified by an Independent Registered Valuer, amounts to approximately ₹672.05 lakhs for property, plant & machinery and ₹509.00 lakhs for investment property. The consideration for the proposed sale shall be settled entirely in cash.

Upon receipt of shareholders' approval, the said assets will be classified as 'Assets Held for Sale' in accordance with Ind AS 105 — Non-Current Assets Held for Sale and Discontinued Operations as notified under the Companies (Indian Accounting Standards) Rules, 2015.

The proposed transaction is at arm's length and in the ordinary course of business, aimed at monetizing non-core assets. The proceeds from the sale are intended to be utilized for new business ventures and strategic initiatives to be undertaken by the Company. The completion of sale is expected to be concluded on or before 31st January 2026, subject to receipt of shareholders' approval.

5) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

Place: Mumbai

Dated: 12th November, 2025

RAMU S. DEORA CHAIRPERSON

DIN: 00312369

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001

website: www.triochemproducts.com CIN: L24249MH1972PLC015544

(Rs. in lakhs) Except EPS

EXT	RACT OF STATEMENT OF UNAUDITED STANDALONE FINANCIAL	RESULTS FOR	THE QUARTE	R AND HALF	YEAR ENDED	30TH SEPTEM	BER, 2025
Sr	Particulars	Quarter Ended			Half Year Ended		For the Year
No		30-Sep-25	30-Jun-24	30-Sep-24	30-Sep-25	30-Sep-24	Ended on
							31-Mar-25
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	29.52	22.10	26.69	51.62	49.66	105.01
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	(14.61)	(15.24)	(4.89)	(29.85)	(14.51)	(24.62)
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	(4.89)	(9.62)	(141.93)	(14.51)	(156.18)	(133.00)
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	(19.26)	(3.06)	(3.66)	(22.32)	(11.50)	(40.01)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	(47.02)	89.27	22.31	42.25	114.44	(55.33)
6	Equity share capital (Face value Rs.10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
7	Other Equity						1,342.19
8	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
	a) Basic (not annualized)	(7.86)	(1.25)	(1.49)	(9.11)	(4.69)	(16.33)
	b) Diluted (not annualized)	(7.86)	(1.25)	(1.49)	(9.11)	(4.69)	(16.33)

Notes:

- 1) The above unaudited standalone financial results of the Company for the quarter and half year ended 30th September 2025 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 12.11.2025. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon.
- The Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunser and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- 4) The Board of Directors, at its meeting held on 24th October 2025, has approved the proposal for the sale of immovable properties, plant & machinery and investment property of the Company situated in Maharashtra. The proposed sale constitutes a Material Related Party Transaction under the provisions of Section 188 of the Companies Act, 2013 and Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accordingly, the transaction shall be subject to approval of shareholders through postal ballot.
 - The said assets proposed to be sold have an aggregate written down value (WDV) of ₹56.92 lakhs. The fair market value of the assets, as determined and certified by an Independent Registered Valuer, amounts to approximately ₹672.05 lakhs for property, plant & machinery and ₹509.00 lakhs for investment property. The consideration for the proposed sale shall be settled entirely in cash.
 - Upon receipt of shareholders' approval, the said assets will be classified as 'Assets Held for Sale' in accordance with Ind AS 105 Non-Current Assets Held for Sale and Discontinued Operations as notified under the Companies (Indian Accounting Standards) Rules, 2015.
 - The proposed transaction is at arm's length and in the ordinary course of business, aimed at monetizing non-core assets. The proceeds from the sale are intended to be utilized for new business ventures and strategic initiatives to be undertaken by the Company. The completion of sale is expected to be concluded on or before 31st January 2026, subject to receipt of shareholders' approval.
- 5) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
- 6) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of consolidated financial results are available on the Stock Exchange website, www.bseindia.com and on the Company's website www.triochemproducts.com

Mumbai

FOR TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA CHAIRPERSON DIN: 00312369

Place: Mumbai

Dated: 12th November, 2025